Abstract Library

#2924 Everolimus in Patients with Advanced Neuroendocrine Neoplasia: A Real-World Study and Analysis of Long Responders

Introduction: Everolimus is a valid therapeutic option for neuroendocrine tumors (NETs); however, data regarding the long responsders in a real-world setting, outside regulatory trials, are scanty.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rinzivillo M

Authors: Rinzivillo M, De Felice I, Magi L, Prosperi D, Iannicelli E,

Keywords: everolimus, neuroendocrine neoplasia, progressive disease, target therapy,

#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors

Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Isiangulova A, Khasanov R,

Keywords: neuroendocrine tumors, somatostatin analogues, target therapy, everolimus, systemic therapy,

#2205 Analysis of MET and RET Expression in Patients with Pancreatic Neuroendocrine Tumors Receiving Everolimus

Introduction: Target therapy has improved the outcome of neuroendocrine tumors (NETs), but little is known about the strategies to overcome the acquired resistance. MET is considered one of the putative mechanisms of resistance. RET is also rearranged in some other endocrine tumors (like thyroid).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Cella C, Barberis M, Spad F, Pisa E, Laffi A,

Keywords: Everolimus, MET, RET,

#2065 Sunitinib in Patients with Pre-Treated Pancreatic Neuroendocrine Tumors: A Real-World Study

Introduction: Besides data reported in a Phase-III trial, data on sunitinib in pancreatic Neuroendocrine Tumors (panNETs) are scanty.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Rinzivillo M

Authors: Rinzivillo M, Gritti S, Pusceddu S, Spallanzani A, Ibrahim T,

Keywords: Sunitinib, neuroendocrine tumors, pancreas, progressive disease, target therapy,

#2042 The Laparoscopic Approach in the Surgical Treatment of the Gastric Neuroendocrine Tumors

Introduction: The incidence of G-NETs has been increased significantly over the last decades, which seems set to continue. The treatment of gastric NETs comprises a wide range of surgical approaches alone or in combination with chemotherapy and target therapy. Laparoscopic surgery is the reasonable method of choice for the partial stomach resection as well as when the gastrectomy is needed.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Zubaryev M, Kolesnik O, Lukashenko A, Ostapenko Y, Boiko A,

Keywords: gastric neuroendocrine tumors, laparoscopic gastric resection, open gastric surgery,